Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors.
MacFarlane AW 4th, Jillab M, Smith MR, Alpaugh RK, Cole ME, Litwin S, Millenson MM, Al-Saleem T, Cohen AD, Campbell KS. MacFarlane AW 4th, et al. Among authors: alpaugh rk. Oncoimmunology. 2017 May 19;6(7):e1330235. doi: 10.1080/2162402X.2017.1330235. eCollection 2017. Oncoimmunology. 2017. PMID: 28811973 Free PMC article.
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
Barta SK, Zain J, MacFarlane AW 4th, Smith SM, Ruan J, Fung HC, Tan CR, Yang Y, Alpaugh RK, Dulaimi E, Ross EA, Campbell KS, Khan N, Siddharta R, Fowler NH, Fisher RI, Oki Y. Barta SK, et al. Among authors: alpaugh rk. Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3. doi: 10.1016/j.clml.2019.03.022. Epub 2019 Apr 3. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31029646 Free PMC article. Clinical Trial.
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials.
Vijayvergia N, Dasari A, Deng M, Litwin S, Al-Toubah T, Alpaugh RK, Dotan E, Hall MJ, Ross NM, Runyen MM, Denlinger CS, Halperin DM, Cohen SJ, Engstrom PF, Strosberg JR. Vijayvergia N, et al. Among authors: alpaugh rk. Br J Cancer. 2020 Apr;122(9):1309-1314. doi: 10.1038/s41416-020-0775-0. Epub 2020 Mar 10. Br J Cancer. 2020. PMID: 32152503 Free PMC article. Clinical Trial.
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV, MacFarlane AW 4th, Jillab M, Arisi MF, Yearley J, Annamalai L, Gong Y, Cai KQ, Alpaugh RK, Cristofanilli M, Campbell KS. Fernandez SV, et al. Among authors: alpaugh rk. Breast Cancer Res. 2020 Dec 2;22(1):134. doi: 10.1186/s13058-020-01371-x. Breast Cancer Res. 2020. PMID: 33267869 Free PMC article.
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Jang HJ, Hostetter G, Macfarlane AW, Madaj Z, Ross EA, Hinoue T, Kulchycki JR, Burgos RS, Tafseer M, Alpaugh RK, Schwebel CL, Kokate R, Geynisman DM, Zibelman MR, Ghatalia P, Nichols PW, Chung W, Madzo J, Hahn NM, Quinn DI, Issa JJ, Topper MJ, Baylin SB, Shen H, Campbell KS, Jones PA, Plimack ER. Jang HJ, et al. Among authors: alpaugh rk. Clin Cancer Res. 2023 Jun 1;29(11):2052-2065. doi: 10.1158/1078-0432.CCR-22-3642. Clin Cancer Res. 2023. PMID: 36928921 Free PMC article. Clinical Trial.
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.
Zibelman M, MacFarlane AW 4th, Costello K, McGowan T, O'Neill J, Kokate R, Borghaei H, Denlinger CS, Dotan E, Geynisman DM, Jain A, Martin L, Obeid E, Devarajan K, Ruth K, Alpaugh RK, Dulaimi EA, Cukierman E, Einarson M, Campbell KS, Plimack ER. Zibelman M, et al. Among authors: alpaugh rk. Nat Commun. 2023 Jul 27;14(1):4513. doi: 10.1038/s41467-023-40028-z. Nat Commun. 2023. PMID: 37500647 Free PMC article. Clinical Trial.
Phase II trial of vorinostat in advanced melanoma.
Haas NB, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S, Adams PD, McBryan T, Wang L, Martin LP, vonMehren M, Alpaugh RK, Zweibel J, Oza A. Haas NB, et al. Among authors: alpaugh rk. Invest New Drugs. 2014 Jun;32(3):526-34. doi: 10.1007/s10637-014-0066-9. Epub 2014 Jan 25. Invest New Drugs. 2014. PMID: 24464266 Clinical Trial.
74 results